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Introduction {#sec001}
============

Visceral leishmaniasis (VL) is a severe systemic infection caused by sandfly-borne trypanosomatous protozoa that has the dog as main reservoir in urban areas \[[@pone.0228176.ref001]\]. Globally distributed, it occurs in Asia, Europe, the Middle East, Africa and the Americas, with Brazil accounting for approximately 90% of all cases on the American continent \[[@pone.0228176.ref001]--[@pone.0228176.ref002]\]. Considered a neglected disease, it is among the six priority endemics in the world (TDR / WHO) \[[@pone.0228176.ref003]\].

It is a systemic spectral disease whose clinical presentation varies from discrete and oligosymptomatic to moderate and severe forms that can progress to death in 90% of cases if left untreated \[[@pone.0228176.ref001],[@pone.0228176.ref002],[@pone.0228176.ref004]\]. The most affected organs in VL are bone marrow, spleen and liver \[[@pone.0228176.ref005]\], justifying the classic parasitic condition, characterized by the presence of prolonged fever, hepatosplenomegaly, anemia \[[@pone.0228176.ref001]--[@pone.0228176.ref005]\].

Cough is a common symptom in VL patients, both in the oligosymptomatic form \[[@pone.0228176.ref006]--[@pone.0228176.ref008]\] and in the classical form of the disease \[[@pone.0228176.ref009]--[@pone.0228176.ref010]\]. Respiratory symptoms at admission have been related to worse prognosis in children, possibly due to existing pulmonary infection \[[@pone.0228176.ref011]\]. However, pulmonary involvement is poorly described. The alteration already reported is interstitial pneumonitis \[[@pone.0228176.ref012]--[@pone.0228176.ref013]\] and bronchopneumonia is often described as a complication and cause of death in patients with VL \[[@pone.0228176.ref009], [@pone.0228176.ref014]--[@pone.0228176.ref015]\]. There are few references on imaging diagnosis of lung lesions \[[@pone.0228176.ref016]\].

Due to the high severity potential of VL, it is of fundamental importance to identify patients who are more likely to evolve to situations of greater severity and death, in order to adopt appropriate prophylactic and therapeutic actions and reduce lethality. The present study aimed to describe the symptoms and pulmonary radiology, to associate respiratory symptoms with tomographic alterations. Better knowledge of the disease will help prevent respiratory complications and reduce mortality, as well as minimize the possible chronic effects of visceral leishmaniasis.

Materials and methods {#sec002}
=====================

We conducted a descriptive study with a cross-sectional design not compared with inpatients at the University Hospital of the Federal University of Sergipe (HU-UFS) located in the municipality of Aracaju, capital of the state of Sergipe, in the Northeast of Brazil. A non-probabilistic sample of inpatients with confirmed diagnosis of VL from January 2015 to July 2018 was used.

Patients of any age which were admitted to the pediatric and infectious wards during the study period and had a confirmed diagnosis of VL were included. A confirmed diagnosis was the finding of the parasite in bone marrow aspirate, the positive immunochromatographic rapid test or reactive immunofluorescence reaction with a titer of 1:80 or higher. Patients transferred from other health units in the region who had already started specific treatment for the parasitosis at the time of admission to the study hospital were excluded.

The patients and/or guardians were approached at the HU-UFS ward and were explained about the research and its methods. After agreeing to participate and signing the free and informed consent form, all patients underwent clinical and epidemiological evaluation, physical examination and anthropometric evaluation, with subsequent completion of an individual evaluation form prepared by the study researcher. Subsequently, the patients were referred for chest radiography and high-resolution computed tomography.

Simple chest X-ray was performed at the radiology department of the HU-UFS, in the posteroanterior and lateral views, at maximum inspiration and with the upright chest within 72 hours of admission. The reports were issued by radiologists of the service.

Tomography was performed according to radiology service availability before or at most within 48 hours of treatment initiation. All examinations were performed without contrast on a Toshiba aquillion 64-channel CT scanner, scanning the entire chest caudocranially for complete inspiration. Cuts were made with 1.0mm thickness, 1.5s time interval. For image reconstruction, a high resolution 512x512 dot matrix algorithm was used. The reports were issued by radiologists of the HU-UFS and later reviewed by another radiologist, also belonging to the hospital staff. In discordant reports, the reviewer radiologist's diagnosis was considered.

An exploratory analysis of the data was performed. Categorical variables were described by absolute and relative frequency. Associations between categorical variables were tested using Pearson's chi-square test with Monte-Carlo and Fisher's exact simulations. Continuous variables were described as mean, standard deviation, minimum and maximum. Adherence to normal distribution was tested by the Shapiro-Wilks test. As this adherence was not verified in any variable, the Mann-Whitney test was used to test the median differences. The significance level adopted was 5% and the software used was the R Core Team 2019.

The project was submitted to the Universidade Federal de Sergipe Research Ethics Committee, approved under CAE 14521913.3.0000.5546.

Results {#sec003}
=======

Sample characterization {#sec004}
-----------------------

Forty-two patients participated in the study. There was a predominance of males (66.6%). It is noteworthy that in some age groups no female patient was observed.

The average age was 19.5 years. Half of the patients were up to 10 years old; Children up to 5 years old represented 28% of the total patients, about 25% of the individuals were aged between 30 and 50 years and only 10% of the patients were over 50 years old.

In 40% of patients, the time elapsed between symptom onset and hospitalization was between 30 and 60 days. The shortest time between the onset of the first symptom and the moment of hospital admission was 5 days, while the maximum was 180 days.

Serological screening for human immunodeficiency virus (HIV) infection was requested for all patients upon admission. HIV / Leishmania coinfection was detected in two patients.

Another patient with VL had co-infection with schistosomiasis mansoni. No other previous infections were reported by the patient or diagnosed during hospitalization. Four patients had previous diseases, namely: diabetes mellitus (one case), diabetes mellitus associated with systemic arterial hypertension (one case), hypothyroidism (one case), hypothyroidism associated with systemic arterial hypertension (one case).

Disease characterization {#sec005}
------------------------

The rk39 rapid test was performed on all patients, with 97% positivity (41/42). The positivity of the myelogram was 64.7% (11/17) and the indirect immunofluorescence was 72.7% (8/11).

The frequency of respiratory manifestations was 49.7%. The most observed respiratory symptom was cough (33.3%), referred to as dry by eight patients (19%) and as productive by six (14.1%). The second respiratory symptom was tachypnea (14.1%), which was always associated with cough. Chest pain was seen in one patient (2.3%) in association with cough and tachypnea.

The general manifestations observed, in order of frequency, were splenomegaly, fever, hepatomegaly, and skin and mucosa pallor.

Results of hemoglobin, neutrophils, platelets, albumin and creatinine can be seen in [Table 1](#pone.0228176.t001){ref-type="table"}.

10.1371/journal.pone.0228176.t001

###### Laboratory tests of patients admitted with VL at HU-UFS, from January 2015 to July 2018.

![](pone.0228176.t001){#pone.0228176.t001g}

  LABORATORY TEST               Mean (± SD)         Maximum   Minimum
  ----------------------------- ------------------- --------- ---------
  **Hemoglobin (g/dl)**         8,67 (±1,41)        11,60     4,38
  **Neutrophils (cells/mm3)**   1.019,55 (±1.002)   4.150     147
  **Platelets (cells/mm3)**     107.264 (±58.648)   287.000   16.000
  **Albumin (g/dl)**            2,93 (±0,72)        4,50      0,72
  **Creatinine (mg/dl)**        0,62 (±0,30)        1,50      0,2

SD = standard deviation.

Specific treatment was performed with glucantime in 21 patients, amphotericin B in 17 and four started treatment with glucantime and ended with amphotericin B. at increased risk of death, according Ministry of Health to clinical and laboratory criteria, two patients. The outcome observed in all cases was medical discharge.

Chest X-ray {#sec006}
-----------

Alterations on simple chest radiography were found in only five patients ([Table 2](#pone.0228176.t002){ref-type="table"}).

10.1371/journal.pone.0228176.t002

###### Chest X-ray results of patients admitted with VL at HU-UFS, from January 2015 to July 2018.

![](pone.0228176.t002){#pone.0228176.t002g}

  CHEST X-RAY                                               N (%)
  --------------------------------------------------------- ----------
  **Changed**                                               5 (11,9)
   Paracardiac alveolar condensation with air bronchogram   1 (2,3)
   Condensation in the middle lobe                          1 (2.3)
   Air bronchogram                                          1 (2,3)
   Bilateral pleural effusion                               1 (2,3)
   Dense streaks on right base                              1 (2,3)
  **Normal**                                                37 (88)

N---absolute frequency. %---relative frequency.

High resolution computed tomography {#sec007}
-----------------------------------

Tomographic changes were found in 59% of patients. The most frequently observed changes were ground-glass opacities, reticular opacities, pleural effusion, and alveolar opacities. The description of all tomographic findings can be seen in [Table 3](#pone.0228176.t003){ref-type="table"}.

10.1371/journal.pone.0228176.t003

###### High resolution computed tomography results of patients admitted with VL at HU-UFS, from January 2015 to July 2018.

![](pone.0228176.t003){#pone.0228176.t003g}

  HRCT                                                                   N (42)   \%
  ---------------------------------------------------------------------- -------- ------
  Reticular opacities                                                    8        19,0
  Ground-glass opacities                                                 7        16,6
  Pleural effusion                                                       5        11,9
  Alveolar opacities                                                     3        7,1
  Bronchiectasis e bronchioloectasis                                     2        4,7
  Peribroncovascular interstitial thickening with micro nodular aspect   2        4,7
  Tree-in-bud opacities                                                  2        4,7
  Atelectasis                                                            2        4,7
  Thickening pleural                                                     2        4,7
  Diffuse interstitial infiltrate                                        1        2,3
  Increased parenchymal attenuation                                      1        2,3
  Dense parenchymal striaes and para-septal emphysema                    1        2,3

N---absolute frequency. %---relative frequency.

Ground-glass opacities were associated with peribronchovascular thickening, bronchiectasis, bronchioloectasis, pleural effusion in one patient.

In a second patient ground-glass opacities were associated with consolidations and tree-in-bud opacities ([Fig 1](#pone.0228176.g001){ref-type="fig"}); with fissural thickening and pleural effusion in a third; with atelectasia in one fourth patient and as isolated HRCT finding in three patients.

![A 29-year-old male with consolidations and tree-in-bud opacities in the left lower lobe, ground-glass opacities right lower lobe, splenomegaly and hepatomegaly.](pone.0228176.g001){#pone.0228176.g001}

Tree-in-bud opacities was also found associated peribronchovascular interstitial thickening ([Fig 2](#pone.0228176.g002){ref-type="fig"}).

![A 45-year-old male with peribronchovascular interstitial thickening and opacities with coalescent micronodular aspect in apical segment of the right upper.](pone.0228176.g002){#pone.0228176.g002}

Reticular opacities were seen associated with pleural effusion in one patient; ground-glass opacity in one second and atelectasis in a third. In five other patients it was the only tomographic alteration found. Pleural effusion was seen associated with interstitial infiltrate, reticular opacity and as a unique finding. Alveolar opacities, increased parenchymal attenuation, dense parenchymal striae, and para-septal emphysema were isolated findings not associated with other changes.

One patient coinfected with HIV and another with Schistosoma had normal HRCT. In the second patient with HIV, pleural thickening and ground-glass opacity were found.

The time interval between symptom onset and hospitalization differed between patients with and without changes HRCT. In patients who had HRCT without pathological findings, the average time between onset of the first symptom and hospital admission was 33.9 days (SD±27.7), while in those who had altered HRCT, this time was 58 days. (SD ±57.2).

There was a statistically significant association between dry cough and HRCT with changes ([Table 4](#pone.0228176.t004){ref-type="table"}).

10.1371/journal.pone.0228176.t004

###### Association between tomographic changes and clinical manifestations of patients admitted with VL at HU-UFS, from January 2015 to July 2018.

![](pone.0228176.t004){#pone.0228176.t004g}

  CLINICAL MANIFESTATIONS   HRCT                  
  ------------------------- --------- ----------- --------------------------------------------------
  **Dry cough**             1 (5)     7 (31,8)    **0,047** [^F^](#t004fn002){ref-type="table-fn"}
  **Productive cough**      3 (15)    3 (13,6)    1,000 [^F^](#t004fn002){ref-type="table-fn"}
  **Diarrhea**              2 (10)    7 (31,8)    0,135 [^F^](#t004fn002){ref-type="table-fn"}
  **Asthenia**              11 (55)   15 (68,3)   0,527 [^F^](#t004fn002){ref-type="table-fn"}
  **Weight lost**           7 (35)    9 (40,9)    0,758 [^F^](#t004fn002){ref-type="table-fn"}

N---absolute frequency. %---relative frequency.

^F^---Fisher's Exact Test.

Physical finding studied were not associated with tomographic changes ([Table 5](#pone.0228176.t005){ref-type="table"}). The association was also not seen with biochemical alterations, as can be seen in [Table 6](#pone.0228176.t006){ref-type="table"}.

10.1371/journal.pone.0228176.t005

###### Association between tomographic changes and physical finding of patients admitted with VL at HU-UFS, from January 2015 to July 2018.

![](pone.0228176.t005){#pone.0228176.t005g}

  PHYSICAL FINDING   HRCT                    
  ------------------ ----------- ----------- ----------------------------------------------
  **Splenomegaly**   10 (100)    21 (95,5)   1,000 [^F^](#t005fn002){ref-type="table-fn"}
  **Hepatomegaly**   18 (90)     18 (81,8)   0,665 [^F^](#t005fn002){ref-type="table-fn"}
  **Pallor**         16 (84,2)   18 (81,8)   1,000 [^F^](#t005fn002){ref-type="table-fn"}
  **Tachypnea**      2 (10)      4 (18,2)    0,665 [^F^](#t005fn002){ref-type="table-fn"}
  **Edema**          1 (5)       3 (13,6)    0,608 [^F^](#t005fn002){ref-type="table-fn"}

N---absolute frequency. %---relative frequency.

^F^---Fisher's Exact Test.

10.1371/journal.pone.0228176.t006

###### Association between tomographic changes and laboratory tests of patients admitted with VL at HU-UFS, from January 2015 to July 2018.

![](pone.0228176.t006){#pone.0228176.t006g}

  LABORATORY TESTS             HRCT                     
  ---------------------------- ------------ ----------- -----------------------------------------------
  **Anemia**                                            1,000 [^F^](#t006fn002){ref-type="table-fn"}
   Severe anemia               1 (6,3)      3 (11,5)    
   Moderate anemia             15 (93,8)    23 (88,5)   
   Mild anemia                 0 (0,0)      0 (0,0)     
  **Neutropenia**                                       0,960 [^QM^](#t006fn003){ref-type="table-fn"}
   Severe neutropenia          6 (37,5)     8 (30,8)    
   Moderate neutropenia        6 (37,5)     11 (42,3)   
   Mild neutropenia            1 (6,2)      2 (7,7)     
   Without neutropenia         3 (18,8)     5 (19,2)    
  **Thrombocytopenia**                                  0,093 [^QM^](#t006fn003){ref-type="table-fn"}
   Severe thrombocytopenia     2 (12,5)     7 (26,9)    
   Moderate thrombocytopenia   6 (37,5)     4 (38,5)    
   Mild thrombocytopenia       8 (50,0)     10 (15,4)   
   Without thrombocytopenia    0 (0,0)      5 (19,2)    
  **Albumin**                                           1,000 [^F^](#t006fn002){ref-type="table-fn"}
   \>3,0 g/dl                  3 (18,8)     6 (23,1)    
   ≤3,0 g/dl                   13 (81,3)    20 (76,9)   
  **Creatinine**                                        1,000 [^F^](#t006fn002){ref-type="table-fn"}
   \<1,2 mg/dl                 16 (100,0)   25 (96,2)   
   1,2--2,0 mg/dl              0 (0,0)      1 (3,8)     
   \>2,0 mg/dl                 0 (0,0)      0 (0,0)     

N---absolute frequency. %---relative frequency.

^F^---Fisher's Exact Test.

^QM^---Qui-quadrado de Pearson's Test.

Discussion {#sec008}
==========

VL is a disease characterized by systemic involvement and a broad spectrum of clinical manifestations. Pulmonary involvement in this parasitosis is even considered uncommon in immunocompetent patients \[[@pone.0228176.ref017]\]. However, the frequency of respiratory symptoms and tomographic changes found in the present study demonstrate that the involvement of the respiratory system in VL is more common than previously thought and deserves attention.

In the late 1990s Cerri *et al* conducted a study using HRCT to prove the interstitial involvement suggested by Duarte, Matta and Corbett ten years earlier. When studying autopsy pulmonary fragments of patients with VL \[[@pone.0228176.ref012],[@pone.0228176.ref013],[@pone.0228176.ref016]\]. The radiological study described reticular opacities, ground-glass opacities, and inter- and intra-lobular septal thickening alterations indicative of interstitial pneumonia \[[@pone.0228176.ref018], [@pone.0228176.ref019]\]. The results of our study, besides confirming, revealed the high frequency of interstitial involvement in the parasitosis. Furthermore, it showed the presence of HRCT findings not demonstrated on chest radiography, such as pleural effusion, parenchymal consolidations, atelectasis, bronchiectasis. Similar results were seen in an imaging study of chronic pulmonary schistosomiasis, which demonstrated that HRCT may show subtle imaging findings lost on plain radiography \[[@pone.0228176.ref020]\].

The lack of description in the tomographic reports of subpleural lesions may suggest the diagnosis of unspecified interstitial pneumonia, a feature that distinguishes it from usual interstitial pneumonia \[[@pone.0228176.ref021],[@pone.0228176.ref022]\].

Frosted glass is a finding considered by many authors to correspond to a pre-fibrotic stage of moderate severity. Even though the disease evolution time was longer in patients with tomographic alteration, the honeycombing pattern was not found, considered the most advanced stage of interstitial disease \[[@pone.0228176.ref018],[@pone.0228176.ref019]\]. Studies in patients with systemic sclerosis have revealed that this pre-fibrotic stage is potentially reversible when appropriate treatment of underlying disease is instituted \[[@pone.0228176.ref023]\]. We consider that, because VL is an acute and treatable disease, the interstitial pneumonia found is a reversible disease. However, patient follow-up may need to be confirmed.

The normality of chest X-rays in the vast majority of patients confirms that this test should not be considered a first choice for interstitial impairment and that HRCT is more sensitive for the diagnosis of pre-fibrotic and potentially treatable early stages of inflammatory bowel disease \[[@pone.0228176.ref023]\].

The predominant respiratory symptom was cough (47%), both dry (19%) and productive (14.1%). The frequency of cough found was very close to that reported by Lima in a review of medical records of children who were hospitalized from January 2010 to December 2012 at HU-UFS \[[@pone.0228176.ref024]\]. Georgiadou *et al*. (2015), in a study conducted in Greece described that cough was the fifth most frequent symptom in VL patients \[[@pone.0228176.ref025]\]. Queiróz in a study conducted in Recife found a frequency of 42.6% of cough \[[@pone.0228176.ref010]\]. Badaró (1986), in a study in Northeastern Brazil, had already shown cough as a frequent symptom also in oligosymptomatic patients, only after diarrhea \[[@pone.0228176.ref007]\].

Tachypnea, present in 14.1% of patients, was the second most common respiratory symptom and was always associated with cough. It is noteworthy that this manifestation is usually described in immunocompetent patients only as presentation of unusual cases of VL \[[@pone.0228176.ref026]--[@pone.0228176.ref028]\].

Chest pain is a rarely described symptom in patients with VL. In this investigation, chest pain was the least mentioned respiratory symptom, occurring in only one patient, associated with cough. This patient had normal chest radiography and alveolar consolidation TACR. Dasgupta (2017), in a case report from India, described chest pain as an initial manifestation of VL, also associated with cough, but in a patient with pleural effusion \[[@pone.0228176.ref017]\].

Respiratory symptomatology in LV is often associated with infecctions \[[@pone.0228176.ref010],[@pone.0228176.ref029]\]. Diamantino (2010) described pneumonia characterized by tachypnea-associated fever and cough in 12.8% of VL patients, with inference of chest X-ray abnormalities in all symptomatic respiratory patients \[[@pone.0228176.ref030]\]. Chest X-ray revealed pneumonia in only two patients in the study, and both reported respiratory symptoms. Nodular tomographic pattern and increased pulmonary opacity found in our sample are considered suggestive of interstitial disease, but may also be due to bacterial infection \[[@pone.0228176.ref017],[@pone.0228176.ref031]\]. Thus, the frequency of secondary bacterial pneumonia may be higher than that found on plain radiographs. It is noteworthy that on chest X-ray, attention cannot be focused only on the infectious process, but also on the search for changes suggestive of interstitial injury, which are peripheral reticular nodular infiltrates and reduced lung volume.

Pulmonary involvement is known in patients co-infected with Leishmania and HIV \[[@pone.0228176.ref026]\]. In these patients, there is usually no impairment of the pulmonary interstitium, but atypical findings, such as solitary pulmonary nodule, pleural effusions, mediastinal adenomegalies. Thus, ground-glass opacity found in a patient with HIV must be due to leishmania infection.

We sought to observe if the pulmonary impairment found could be associated with biochemical alterations such as hypoalbuminemia, anemia, neutropenia, thrombocytopenia or creatinine elevation. Such an association was not found.

The most commonly reported general clinical manifestations in our study, namely splenomegaly, hepatomegaly, fever, pallor, correspond to the classic signs of the disease \[[@pone.0228176.ref024], [@pone.0228176.ref032], [@pone.0228176.ref033]\].

The diagnosis of VL may be based on clinical and epidemiological data, parasitological methods, immunodiagnostic methods and molecular methods \[[@pone.0228176.ref001],[@pone.0228176.ref002]\]. The most commonly used diagnostic method in this study was the rK39 rapid test, a noninvasive and economical test considered highly sensitive and specific in Brazil and the Indian subcontinent \[[@pone.0228176.ref034]\]. The series of Xavier-Gomes *et al*. (2009) obtained 100% positivity in this exam, while in our sample, its positivity was 97% \[[@pone.0228176.ref035]\].

Conclusions {#sec009}
===========

The present study was a pioneer in the joint investigation of respiratory symptomatology, tomographic alterations. The cross-sectional design did not allow establishing causal inferences between the studied variables, which constitutes a limitation of the research. This was the design chosen because we did not consider it prudent to subject healthy patients to a CT scan to have a control group. Our results were relevant for pioneering, but above all, for bringing recent and objective knowledge about respiratory involvement in a highly incident, potentially serious and lethal disease.

Our findings recommend that patients with respiratory symptomatology undergo HRCT, since conventional chest radiography cannot detect the interstitial pulmonary impairment in VL. Transthoracic ultrasonography, a diagnostic method recently considered useful in the diagnosis of interstitial diseases, could also be an alternative for this evaluation. Spirometry, a low complexity test directed to the respiratory functional study, could also be inserted in the routine of patients with VL, as well as in outpatient follow-up, since pulmonary interstitial impairment may result in restrictive functional alteration.
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PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1. As many co-morbidity / past illness may cause pulmonary changes, how changes of lung in radiology was attributed to Visceral Leishmaniasis? As authors mention in conclusion that "cross-sectional design did not allow establishing causal inferences between the studied variables" -- this should be conversed in the discussion.

2\. What is the exact number of cases of the present study? According to table 5, total cases classified according to severity of anemia is 42, though the total number of cases classified according to severity plus absence of Neutropenia is 39.

3\. Inclusion and exclusion criteria (beside "Patients transferred from other health units who had already started treatment at the unit of Origin") of the present study must be defined.

4\. Clinical features / physical finding should be depicted in a separate table.

5\. Rationality of correlating some parameters (for example Thrombocytopenia) with HRCT changes of lung should be explained.

6\. As bone marrow examination was not done in every case, rationality of the diagnosis by serological investigations should be discussed.

7\. Results of radiological finding of the present study should be compared with other similar studies. Was any additional significant findings obtained in the present study?

8\. Some characteristic image of changes in the lung as depicted in CT / X ray should be incorporated.

9\. Units of biochemical tests in Table 5 should be mentioned.

10\. Appropriate symbol for fractional number should be placed.

11\. All reference must be quoted according to instructions to authors of the journal.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Sudipta Chakrabarti

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Some additional information / modification of the manuscript required as depicted in comments to authors.

Comment to Authors

1\. As many co-morbidity / past illness may cause pulmonary changes, how changes of lung in radiology was attributed to Visceral Leishmaniasis? As authors mention in conclusion that "cross-sectional design did not allow establishing causal inferences between the studied variables" -- this should be conversed in the discussion.

RESPONSE:

We evaluated the presence of previous diseases, co-infections and comorbidities. We found HIV / Leishmania coinfection in two patients and in another schistosomiasis mansoni. No other infections were reported by the patient or diagnosed during hospitalization. Four patients had comorbidities: diabetes mellitus (one case), diabetes mellitus associated with systemic arterial hypertension (one case), hypothyroidism (one case), hypothyroidism associated with systemic arterial hypertension (one case). Tomographic changes were present, regardless of past or associated VL diseases, including in children, adolescents and young adults, which corresponds to about 75% of the sample. Considering the importance of this information, we added in the results and made the necessary considerations in the discussion of our manuscript. We added the consideration about the study design and the establishment of causal inferences in the discussion.

2\. What is the exact number of cases of the present study? According to table 5, total cases classified according to severity of anemia is 42, though the total number of cases classified according to severity plus absence of Neutropenia is 39.

RESPONSE: the exact number of cases of the present study is 42. The table was retified. Excuse us for the mistake.

3\. Inclusion and exclusion criteria (beside "Patients transferred from other health units who had already started treatment at the unit of Origin") of the present study must be defined.

RESPONSE: The hospital where the study was conducted is a referral hospital for Leishmaniasis treatment and receives patients from other hospitals. Patients diagnosed with VL who were already on specific treatment when admitted to HU-UFS did not participate in the study. This clarification had been added in the manuscript.

4\. Clinical features / physical finding should be depicted in a separate table.

RESPONSE: We performed the separation in different tables.

5\. Rationality of correlating some parameters (for example Thrombocytopenia) with HRCT changes of lung should be explained.

RESPONSE: We made that explanation in the discussion

6\. As bone marrow examination was not done in every case, rationality of the diagnosis by serological investigations should be discussed.

RESPONSE: We made that explanation in the discussion

7\. Results of radiological finding of the present study should be compared with other similar studies. Was any additional significant findings obtained in the present study?

RESPONSE: There is a similar study in the medical literature conducted in past decades (reference 16), which was cited in the text. We made a more detailed comparison of our study with this one previous study.

8\. Some characteristic image of changes in the lung as depicted in CT / X ray should be incorporated.

RESPONSE: We have incorporated images into the manuscript.

9\. Units of biochemical tests in Table 5 should be mentioned.

RESPONSE: We added Units of biochemical tests in Table

10\. Appropriate symbol for fractional number should be placed.

RESPONSE: We have incorporated Appropriate symbol for fractional number.

11\. All reference must be quoted according to instructions to authors of the journal.

RESPONSE: We quoted all reference according to instructions to authors of the journal.
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